MDSpire - Summary
From the Journals

CAR-Engineered Astrocytes in Alzheimer’s Models

Preclinical findings show engineered astrocytes reduce amyloid buildup in mouse models and demonstrate a potential therapeutic approach

  • March 25, 2026

  • 2 min

Share

Research has developed CAR-expressing astrocytes which can clear amyloid-β associated with Alzheimer's disease. In vitro tests and mouse models show that these modified astrocytes effectively reduce amyloid plaques when delivered via adeno-associated viral vectors. This innovative method offers a self-sustaining system for Aβ clearance, contrasting with current high-dose monoclonal antibody therapies that pose safety risks. The study highlights variations in CAR designs impacting biological responses and suggests further investigation for human application.

Original Source(s)

CAR-Engineered Astrocytes in Alzheimer’s Models

  • March 25, 2026

Related Content

Tau Biomarker Expands Beyond Alzheimer’s

Study finds elevated phosphorylated tau in AL and ATTR amyloidosis, suggesting a potential blood biomarker for amyloid-related neuropathy

  • March 25, 2026

  • 3 min
Researchers Propose TMD Definition for GBD

Consensus description may support inclusion in Global Burden of Disease estimates.

ALS Trial Tests Celecoxib–Ciprofloxacin Combination

Dual-drug therapy showed signals of slower disease progression and reduced complications in patients with ALS.